Valproic acid neuroprotection in 6-OHDA lesioned rat, a model for parkinson's disease
Authors:
- Barbara MontiBarbara Monti
- Daniele MercatelliDMDaniele Mercatelli
- Antonio ContestabileACAntonio Contestabile
Open Access
- 1 January 2012
- journal article
- Published by Herbert Publications PVT LTD in HOAJ Biology
- Vol. 1 (1)
Abstract
Background: Valproic acid (VPA) a long standing anti-epileptic and anti-manic drug has been recently investigated as a neuroprotective molecule, in relation to its action as an inhibitor of histone deacetylasesKeywords
This publication has 23 references indexed in Scilit:
- Parkinson's disease: Insights from non-traditional model organismsProgress in Neurobiology, 2010
- Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson’s disease2010
- Genetic mouse models of Parkinson’s disease2010
- Neurotoxic in vivo models of Parkinson’s disease2010
- Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid NeuroprotectionCurrent Molecular Pharmacology, 2009
- The 6-hydroxydopamine model: News from the pastParkinsonism & Related Disorders, 2008
- Endogenous α-Synuclein Is Induced by Valproic Acid through Histone Deacetylase Inhibition and Participates in Neuroprotection against Glutamate-Induced ExcitotoxicityJournal of Neuroscience, 2006
- Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal PathwayExperimental Neurology, 2002
- Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cellsThe EMBO Journal, 2001
- Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the RatExperimental Neurology, 1998